Kalowski Lee
Known title: CFO and PresidentCIK: 0001618273
Associated companies
Transaction History
| QTTB | ▼ Sell | Open Market | 3,972 | $66K | 8/25/2026 | View on chart |
| QTTB | ▲ Buy | Grant | 53,250 | $0 | 7/16/2026 | View on chart |
| QTTB | ▼ Sell | Open Market | 3,995 | $18K | 2/25/2026 | View on chart |
| QTTB | ▲ Buy | Grant | 53,250 | $0 | 2/24/2026 | View on chart |
| QTTB | ▼ Sell | Open Market | 9,072 | $31K | 12/2/2025 | View on chart |
| QTTB | ▼ Sell | Open Market | 4,240 | $8K | 8/26/2025 | View on chart |
| QTTB | ▲ Buy | Grant | 53,250 | $0 | 2/24/2025 | View on chart |
| BCYC | ▼ Sell | Open Market | 376 | $8K | 4/3/2023 | View on chart |
| BCYC | ▲ Buy | Grant | 17,500 | $0 | 1/3/2023 | View on chart |
| BCYC | ▼ Sell | Open Market | 1,815 | $53K | 1/3/2023 | View on chart |
| BCYC | ▲ Buy | Grant | 15,000 | $0 | 1/3/2022 | View on chart |
| BCYC | ▲ Buy | Option Exercise | 10,000 | $98K | 9/2/2021 | View on chart |
| BCYC | ▼ Sell | Open Market | 10,000 | $400K | 9/2/2021 | View on chart |
| BCYC | ▲ Buy | Option Exercise | 7,950 | $69K | 8/27/2021 | View on chart |
| BCYC | ▼ Sell | Open Market | 7,950 | $279K | 8/27/2021 | View on chart |
| BCYC | ▲ Buy | Option Exercise | 550 | $5K | 8/26/2021 | View on chart |
| BCYC | ▼ Sell | Open Market | 550 | $19K | 8/26/2021 | View on chart |
| BCYC | ▲ Buy | Option Exercise | 7,500 | $12K | 8/23/2021 | View on chart |
| BCYC | ▼ Sell | Open Market | 7,500 | $248K | 8/23/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Q32 Bio to Present Late‑Breaking Results of Bempikibart Trial at EADV Congress
Q32 Bio will present late‑breaking results from Part B of its SIGNAL‑AA Phase 2a study of Bempikibart for alopecia areata at the European Academy of Dermatology and Venereology Congress. The company also shared additional 36‑week data from the same study earlier in the congress. These updates provide new information on the drug’s safety and efficacy profile, which may influence market perception of the company’s pipeline.
Q32 Bio to Present Late‑Breaking Results of Bempikibart Trial at EADV Congress. Q32 Bio will present late‑breaking results from Part B of its SIGNAL‑AA Phase 2a study of Bempikibart for alopecia areata at the European Academy of Dermatology and Venereology Congress. The company also shared additional 36‑week data from the same study earlier in the congress. These updates provide new information on the drug’s safety and efficacy profile, which may influence market perception of the company’s pipeline.